Gennatas C, Michalaki V, Gennatas S, Papalambros E
Oncology Clinic, Department of Surgery, Areteion Hospital, University of Athens, Greece.
Anticancer Res. 2008 May-Jun;28(3B):1923-6.
Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is increasingly replacing intravenous i.v. 5-FU/leucovorin in colorectal cancer treatment. THE AIM of this study was to evaluate efficacy and safety of the combination chemotherapy of irinotecan plus capecitabine (XELIRI), in patients with advanced colorectal adenocarcinoma.
Forty patients received first-line chemotherapy with capecitabine (1.000 mg/m2 twice daily) on days 1-14 and irinotecan (240 mg/m2) on day 1 of a 21-day cycle. Baseline characteristics: 24 men, 16 women; median age 64.5 years. Most common metastatic sites were the liver (55%), lymph nodes (45%), lung (22.5%) and bones (17.5%).
There were 12 partial responses (30%), 11 cases of stable disease (27.5%), and 17 cases of disease progression (42.5%). The median survival was 16 months (range, 6-26 months) and median progression-free survival was 7 months (range, 3-14 months). Frequently encountered therapy-related events were leukopenia and gastrointestinal side effects including diarrhea.
XELIRI is a well-tolerated regimen, with an activity comparable to, but more convenient than, irinotecan-5-FU i.v. combinations in patients with previously untreated advanced colorectal cancer.
卡培他滨是一种口服的5-氟尿嘧啶（5-FU）前体药物，在结直肠癌治疗中越来越多地取代静脉注射的5-FU/亚叶酸钙。本研究的目的是评估伊立替康联合卡培他滨（XELIRI）对晚期结直肠腺癌患者进行化疗的疗效和安全性。
40例患者接受一线化疗，在21天周期的第1 - 14天给予卡培他滨（1000mg/m²，每日两次），第1天给予伊立替康（240mg/m²）。基线特征：男性24例，女性16例；中位年龄64.5岁。最常见的转移部位是肝脏（55%）、淋巴结（45%）、肺（22.5%）和骨骼（17.5%）。
有12例部分缓解（30%），11例病情稳定（27.5%），17例病情进展（42.5%）。中位生存期为16个月（范围6 - 26个月），中位无进展生存期为7个月（范围3 - 14个月）。常见的与治疗相关的事件是白细胞减少和胃肠道副作用，包括腹泻。
XELIRI是一种耐受性良好的方案，对于先前未治疗的晚期结直肠癌患者，其活性与伊立替康 - 5 - FU静脉联合方案相当，但更方便。
